ANI Pharmaceuticals Inc (NASDAQ: ANIP ) reported upbeat earnings for the second quarter on Friday .
The company posted quarterly earnings of $2.21 per share which beat the analyst consensus estimate of $2.05 per share. The company reported quarterly sales of $266.044 million which beat the analyst consensus estimate of $260.128 million.
ANI Pharmaceuticals affirmed FY2026 adjusted EPS guidance of $9.19-$9.69 and also affirmed sales forecast of $1.080 billion-$1.140 billion.
ANI Pharmaceuticals shares fell 3.2% to trade at $75.73 on Monday.
These analysts made changes to their price targets on ANI Pharmaceuticals following earnings announcement.
Canaccord Genuity analyst Gary Nachman maintained the stock with a Hold and lowered the price target from $91 to $90. Guggenheim analyst Vamil Divan maintained the stock with a Buy and cut the price target from $124 to $119.Considering buying ANIP stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Markets Trading Ideas News Analyst Ratings Price Target Earnings PT Changes